Drug Targets for Ovarian Cancer

Drug Targets VEGF for Ovarian Cancer with Approved Drugs

Drug targets Cancer drugs Company
VEGF-A Bevacizumab Roche

VEGF also seems to be important in pathological angiogenesis. Shen et al. showed that VEGF expression assessed by immunohistochemistry was an independent prognostic indicator of overall survival time in patients with epithelial ovarian cancer. Raspollini et al. presented similar results to those of Shen et al. in advanced disease (FIGO stage III). Recently, by using a tissue microarray of 339 primary ovarian tumors, Duncan et al. immunohistochemically assessed VEGF expression and noted that VEGF was an independent predictor of prognosis on multivariate analysis, although there was no correlation between VEGF and any clinicopathological variables. By performing real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) in cases of epithelial ovarian cancer, we demonstrated that tumors might acquire an aggressive tumor phenotype in the presence of VEGF expression. These results prompted us to consider the potential for anti-VEGF therapy in malignant tumors, including epithelial ovarian cancer.

Drug Targets PARP-1 for Ovarian Cancer with Approved Drugs

Drug targets Cancer drugs Company
PARP-1 olaparib KuDOS Pharmaceuticals and AstraZeneca
PARP-1 Rucaparib Clovis Oncology

Initial observations showed that PARP-1 inhibitors had cytotoxic effects on BRCA1- or BRCA2- deficient cells and human tumors. This was caused by the lack of repair of SSB due to PARP-1 inhibition and the lack of DSB repair because of HR dysfunction due to BRCA mutations. In the initial proof-of-concept study with the PARP-1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, 28% of patients with ovarian cancer achieved an objective response (RECIST criteria) of a median duration of 7.0 months. The important finding of this study was the observation of objective antitumor activity in platinum-resistant patients at dosages well below the recommended/maximum tolerated doses.

Drug targets for Ovarian cancer: Related Information